Merit Medical Systems stock faces valuation scrutiny amid post-earnings pullback and growth outlook

Merit Medical Systems (ISIN: US59001A1025) shares have declined sharply year-to-date on Nasdaq, trading around US$66-83 amid mixed valuation signals after strong Q4 2025 earnings. Investors weigh premium P/E against DCF upside as healthcare demand persists. Why DACH portfolios should monitor this medtech name now.

Merit Medical Systems stock has pulled back significantly in 2026, with shares down over 22% year-to-date on Nasdaq in US dollars. This follows robust Q4 2025 earnings released February 24, 2026, where the company beat estimates with EPS of $1.04 versus $0.96 expected and revenue of $382.46 million topping $372.47 million forecasts. The market now questions if the dip creates a buying opportunity or signals overvaluation in a high P/E environment.

As of: 23.03.2026

By Dr. Elena Voss, Senior MedTech Analyst – Merit Medical Systems exemplifies resilient growth in interventional devices, but recent share weakness tests investor patience amid sector rotations.

Recent Earnings Beat Masks Broader Pressure

Merit Medical Systems reported Q4 2025 results that exceeded expectations, driving initial optimism. Earnings per share hit $1.04, surpassing consensus by $0.08, while quarterly revenue surged 13.2% year-over-year to $382.46 million. This performance underscores strength in core segments like peripheral interventions and cardiac rhythm management.

Yet, the stock on Nasdaq has traded lower, last around US$66.71 in recent analysis, reflecting a 2.4% daily drop and 4.6% weekly decline. Year-to-date, shares are down 22.8%, with a 30-day return of -18.9%. Momentum has faded despite five-year gains, prompting valuation debates.

For DACH investors, this volatility highlights medtech's sensitivity to U.S. market rotations. European portfolios heavy in healthcare may find Merit a diversification play, given its global footprint including Germany and France.

Valuation Metrics Signal Caution and Opportunity

Trading at a P/E of 30.9x on Nasdaq in US dollars, Merit Medical appears premium to peers. The U.S. medical equipment industry averages 26.9x, with peers at 16.4x and fair P/E estimated at 24.9x. This suggests investors pay more for each earnings dollar compared to competitors.

Revenue stands at $1,515.91 million with net income of $128.49 million, supporting growth expectations. However, trailing EPS of $1.97 yields a P/E of 42x, forward at 24.55x. Earnings growth is projected at 11.28% to $3.75 per share next year.

Contrasting views emerge from DCF models showing 18.2% undervaluation, with intrinsic value at $81.59 versus recent US$66.71 price on Nasdaq. Analyst targets reach US$102, implying substantial upside if execution holds.

Business Model and Segment Strength

Merit Medical designs, manufactures, and markets single-use devices for interventional, diagnostic, and therapeutic procedures. Key markets include the U.S., China, Japan, Germany, France, and the UK. Products target cardiology, radiology, endoscopy, and peripheral vascular fields.

Growth drivers include rising procedure volumes driven by aging populations and minimally invasive techniques. The company's balance sheet is solid, supporting acquisitions and R&D. Recent quarters show consistent beats, with Q2 2025 EPS at $1.01 versus $0.85 expected.

For medtech, metrics like order backlog, pricing power, and regulatory approvals matter most. Merit benefits from strong execution, but supply chain risks in China exposure warrant watch.

Guidance and Forward Outlook

Full-year 2026 EPS guidance is $3.52-$3.72, above consensus $3.34, with revenue at $1.5 billion matching estimates. Upcoming Q1 2026 earnings loom, with consensus EPS $0.81. Management emphasizes sustained double-digit growth.

Analysts forecast 11%+ earnings expansion, fueled by product launches and market share gains. However, P/E premium demands flawless delivery. Shares on Nasdaq in US dollars must stabilize to attract fresh capital.

Risks and Key Challenges Ahead

High P/E leaves little margin for error if growth slows. Recent pullbacks signal sector rotation away from healthcare amid broader market shifts. Inventory cycles and hyperscaler-like demand in medtech could pressure margins.

Regulatory hurdles, especially in Europe and Asia, pose risks. Competition from larger players like Boston Scientific intensifies. Macro factors, including U.S. election cycles or inflation, could impact procedure volumes.

Geopolitical tensions affect China sales, a growth market. Investors should monitor Q1 results for confirmation of momentum.

Relevance for DACH Investors

German-speaking investors in Germany, Austria, and Switzerland favor stable healthcare exposures. Merit Medical's European sales in Germany and France align with DACH medtech hubs like Munich and Zurich. Currency-hedged ETFs or direct Nasdaq access via brokers like Consorsbank or Swissquote simplify entry.

DACH portfolios benefit from U.S. medtech diversification, reducing EM exposure risks. With EU aging demographics mirroring U.S. trends, demand tailwinds persist. Tax-efficient structures like German Depot models support long-term holds.

Recent undervaluation signals per DCF appeal to value-oriented Swiss investors. Monitor for post-Q1 rebound on Nasdaq in US dollars.

Strategic Positioning in MedTech Landscape

Merit's focus on single-use devices minimizes infection risks, a post-pandemic priority. Innovations in embolization and access products drive margins. Partnerships with key hospitals bolster recurring revenue.

Sector catalysts include AI integration in diagnostics and outpatient shifts. Merit is well-positioned, but execution on pipeline remains key. Balance sheet strength enables bolt-on M&A, echoing peers' strategies.

Comparative P/E analysis shows Merit trading above industry but justified by growth if delivered. DACH analysts may view it as a quality compounder.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.